SMSybil A. McAuley

Sybil A. McAuley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sybil A. McAuley has a total of 209 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The never‐asked: Understanding the gap in emotional support for people living with diabetes

    by Kathleen Hare, Sybil A. McAuley, Steven Trawley

    Aims: Diabetes distress affects about one‐third of adults with diabetes and is associated with poorer health outcomes, yet routine screening by healthcare professionals remains uncommon. This study examined person‐reported experiences of emotional health screening across a large Australian sample. Methods: Adults with diabetes completed an online cross‐sectional survey involving emotional health screening and assessing whether their diabetes healthcare provider had ever asked about their diabetes‐related emotional health. Participant characteristics were compared by ‘asked’ status. A pre‐specified multivariable logistic regression identified demographic and clinical predictors of never being asked. Open text responses were analysed using inductive thematic analysis. Results: Of the 1092 eligible respondents (median age 57 years [IQR 44–67]; n = 676 women [62%]; diabetes duration 10 years [4–21]; n = 274 [25%] with type 1 diabetes; n = 391 [36%] using continuous glucose monitoring [CGM]), most ( n = 797; 73%) reported never being asked about their diabetes‐related emotional health by their diabetes healthcare provider. Approximately 42% screened positive for diabetes distress (PAID‐5 ≥ 8), with similar prevalence irrespective of ‘asked’ status. CGM use was the strongest predictor of being asked about emotional health, with CGM non‐users having nearly double the odds of never being asked (OR = 2.00, 95% CI 1.19–3.33, p = 0.007). Seven qualitative themes emerged, highlighting the emotional burden of diabetes, inconsistent care and participants' desire to be asked about emotional wellbeing. Conclusions: Most adults with diabetes in Australia are not asked about their emotional health, despite guideline recommendations. Elevated distress is common yet under‐identified. Systemic changes are needed to close this gap.

  • Does ageing increase vulnerability to hypoglycaemia and hyperglycaemia? A systematic review of physiological and cognitive responses

    by Steven Trawley, Antoine Christiaens, Amanda N. Stephens, Sybil A McAuley, Angus Forbes, Giuseppe Maltese, Ahmed H. Abdelhafiz, Alan J. Sinclair

  • Open Access

    Finger‐stick glucose testing as an institutional stressor: Staff perspectives from long‐term care

    by Steven Trawley, Suzanne Kapp, Jieli Li, Alan Sinclair, Katharina Mattishent, Patrick Olivier, Grace Garces, Sybil A. McAuley, Khadija Dossa, Rameez Hassan, et al.

  • Open Access

    Eye Health Among Islet Cell Transplant Recipients With Long-duration Type 1 Diabetes

    by Hye Jin Kwon, Sybil A. McAuley, Richard J. MacIsaac, Thomas W.H. Kay, Glenn M. Ward

    Background.: Diabetic retinopathy (DR) is the commonest cause of blindness among people with type 1 diabetes (T1D) and can progress over time. In Australia, islet cell transplantation (ICT) is available for adults with T1D experiencing recurrent severe hypoglycemia. Rapid improvement in glycemia, which can occur post-ICT, may lead to “early worsening” of DR and warrants investigation. This study explored eye health outcomes among ICT recipients. Methods.: This retrospective study examined all ICT recipients at a single tertiary institution in Victoria, Australia, 2007–2022 inclusive. Recipients of successful ICT, with available eye health information pre- and posttransplantation, were included. Eye health outcomes were assessed relative to ICT for changes in DR and other major retinal pathologies. Results.: Sixteen recipients (30 eyes) with T1D duration median 31 y (interquartile range, 26–44) were followed up for 5 y (interquartile range, 4–9). At 12 mo post-ICT, hemoglobin A 1c improved by −1.2 percentage points (−1.9 to −0.5; P < 0.001). Pre-ICT, 9 of 16 recipients (56%) had DR, with 4 recipients having proliferative DR. During follow-up post-ICT, 4 of 16 recipients (25%) had worsening eye outcomes; there were no new cases of proliferative DR. Four recipients had “early worsening” signs, not associated with progression of DR. Recipients experiencing worsening eye outcomes post-ICT exhibited higher hemoglobin A 1c and lower C-peptide levels during 12 mo compared with recipients who had stable eye outcomes ( P = 0.02 and P = 0.01, respectively). Conclusions.: These findings highlight the potential positive impact of ICT to stabilize eye health among a small group of ICT recipients with long-duration type 1 diabetes. An extended systematic evaluation of eye health pre- and post-ICT is required to monitor both short-term and long-term eye health among transplant recipients.

  • Open Access

    Medication Use in Type 1 Diabetes and the Association with Socioeconomic Disadvantage: Analysis of a National Linked Dataset

    by Ella Zomer, Jedidiah I. Morton, Lei Chen, Stella Talic, Sybil A. McAuley, Elizabeth A. Davis, Timothy W. Jones, Kate E. Lomax, Dianna J. Magliano, Jonathan E. Shaw, et al.

    Objectives: To explore trends in the receipt of commonly prescribed medications (beyond insulin) in people with type 1 diabetes in Australia, including polypharmacy, and to investigate socioeconomic disparities across these trends. Methods: A retrospective analysis of 68,287 people with type 1 diabetes registered on the National Diabetes Services Scheme between 2013 and 2019, and linked to the Australian pharmaceutical claims database to capture medication use. The proportion of people with type 1 diabetes dispensed a medication class was assessed in each year, and by levels of Index of Relative Social Disadvantage. Results: The study population comprised 37,055 (54.3%) males and 31,232 (45.7%) females captured between 2013 and 2019, with an overall median age of 38.8 (interquartile range [IQR]: 26.1–53.3) years and median diabetes duration of 17.0 (IQR: 7.9–25.7) years. The median number of medications used in the study population was five (IQR: 3–8). Trends in receipt of commonly prescribed medications remained relatively stable between 2013 and 2019, except for the use of noninsulin (adjuvant) glucose-lowering agents, which increased. In 2019, compared with people in the least disadvantaged areas, those in the most disadvantaged areas were more likely to be receiving adjuvant glucose-lowering therapy (crude rates 21.5% vs. 11.6%), antihypertensive therapies (36.1% vs. 28.8%), lipid-lowering therapies (35.7% vs. 29.7%), antithrombotic medication (8.9% vs. 5.6%), proton pump inhibitors (25.2% vs. 17.1%), medications for asthma (13.2% vs. 8.4%), and medications for mental health (27.5% vs. 21.5%). Polypharmacy (defined as ≥5 medications) was more likely in those in the most disadvantaged areas compared with those in the least disadvantaged areas (58.8% vs. 48.5%). Even after adjustment for patient factors, differences in medication use and polypharmacy across socioeconomic strata persisted. Conclusions: Receipt of commonly prescribed medications in type 1 diabetes and polypharmacy were associated with increased socioeconomic disadvantage.

  • Open Access

    Diabetes distress screening using PAID‐5 and PAID‐1 among adults attending a tertiary multidisciplinary type 1 diabetes clinic

    by Jonathan Vu, Krisha Solanki, Jenny McKay, Kavita Kumareswaran, Isobel Duncan, Annita Joseph, Tomasz J. Block, Anthony W. Russell, Sophia Zoungas, Steven Trawley, et al.

    Aims: Living with type 1 diabetes can be challenging, and diabetes distress may be overlooked during time‐constrained clinical assessments. Screening for diabetes distress with the one‐item Problem Areas in Diabetes Scale (PAID)‐1, in conjunction with the five‐item PAID‐5, may offer an efficient method to improve type 1 diabetes assessment. We aimed to evaluate the utility of this approach to identify possible diabetes distress and its clinically significant covariates.Methods: We performed a retrospective, real‐world, cross‐sectional study of adults attending a multidisciplinary type 1 diabetes outpatient clinic at a tertiary centre from October 2023 to September 2024, inclusive. Screening was conducted using PAID‐5 (incorporating PAID‐1) during the initial consultation.Results: There were 160 adults included (median age 38 years [IQR 30–52]; type 1 diabetes duration 16 years [4–24]; n = 138 [86%] were using continuous glucose monitoring [CGM]). PAID‐5 median score was 8 [4–12]; 83 individuals (52%) had a score ≥8, indicating possible diabetes distress. Higher diabetes distress screening scores were associated with CGM metrics indicative of hyperglycaemia; no associations were observed with CGM‐detected hypoglycaemia. PAID‐1 had sensitivity 81% and specificity 96% for PAID‐5‐detected diabetes distress.Conclusions: A high prevalence of diabetes distress was detected on screening among adults attending a tertiary type 1 diabetes service. This highlights the importance of psychological assessment and implementation of management strategies for diabetes distress to reduce the burden of living with type 1 diabetes. Our findings support the use of the PAID‐1 as a rapid screening tool to assess for diabetes distress.


  • Kidney Disease: The Forgotten Legacy of Type 1 Diabetes

    by Merlin C. Thomas, Sophia Zoungas, Nordin M.J. Hanssen, Sybil A. McAuley, Mark E. Cooper

    Type 1 diabetes is associated with a progressive decline in kidney function. With improved survival, more individuals with type 1 diabetes are reaching an age where irreversible loss of kidney function can impact health and clinical outcomes. Although current standard of care has markedly reduced the incidence of fast-progressing kidney disease characterized by heavy albuminuria, and improved patient survival, these same interventions have not slowed kidney decline in most patients. An urgent need remains to develop a different foundational approach to type 1 diabetes with early kidney protection considered as important as glucose control. Toward this goal, a number of new renoprotective strategies have emerged over the last decade, including glucagon-like peptide 1 receptor agonists, aldosterone antagonists, and sodium–glucose cotransporter 2 inhibitors. For each therapy unequivocal activity has been demonstrated in patients with type 2 diabetes and kidney disease, which has prompted some clinicians to use agents off-label in patients with type 1 diabetes, so pressing is their need. However, before such important benefits can be translated to patients with type 1 diabetes, the risk of serious adverse effects must be carefully considered and the balance of efficacy and safety verified in clinical trials. In this review we consider the potential role of adjunctive therapy in type 1 diabetes in improving kidney outcomes.


  • Automated Insulin Delivery Effects During Driving Among Older Adults with Type 1 Diabetes in a Randomized Trial

    by Steven Trawley, Hye Jin Kwon, Sara Vogrin, Peter G. Colman, Spiros Fourlanos, Melissa H. Lee, Richard J. MacIsaac, David N. O’NEal, Niamh A. O’REgan, Vijaya Sundararajan, et al.

    Dysglycemia among drivers with type 1 diabetes (T1D) is associated with impaired driving performance, and glucose levels “above 5 to drive” are often recommended for insulin-treated drivers. Evidence for diabetes treatments that support euglycemia while driving is minimal, particularly for older drivers. In this randomized, crossover trial involving adults aged ≥60 years with T1D, we used continuous glucose monitoring (CGM) during driving to compare the first-generation closed-loop automated insulin delivery (AID) versus a sensor-augmented pump therapy. There were 1894 trips undertaken by 8 drivers (median age 68 years [IQR: 64–70]). During AID versus sensor-augmented pump, time in range >5.0–10.0 mmol/L was greater (100% [0–100] vs. 81% [0–100]; P = 0.033) and fewer trips had any CGM >16.7 mmol/L (3.5% vs. 6.4%; P = 0.006). Three percent of all trips included CGM P = 0.52). System alerts occurred in 10% of all trips, with no between-stage difference (9% vs. 11%; P = 0.078). First-generation AID reduces hyperglycemic driving among older drivers with T1D, without increasing hypoglycemia. Developing dedicated “driving-mode” settings could prioritize safety while minimizing distraction. Trial Registration: ACTRN12619000515190.


  • Effect of Interrupting Prolonged Sitting with Frequent Activity Breaks on Postprandial Glycemia and Insulin Sensitivity in Adults with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy: A Randomized Crossover Pilot Trial

    by Robyn Larsen, Frances Taylor, Paddy C. Dempsey, Melitta McNarry, Kym Rickards, Parneet Sethi, Ashleigh Homer, Neale Cohen, Neville Owen, Kavita Kumareswaran, et al.

    Objective: This study examined acute effects of interrupting prolonged sitting with short activity breaks on postprandial glucose/insulin responses and estimations of insulin sensitivity in adults with type 1 diabetes (T1D). Method: In a randomized crossover trial, eight adults (age = 46 ± 14 years [mean ± SD], body mass index [BMI] = 27.2 ± 3.8 kg/m 2 ) receiving continuous subcutaneous insulin infusion (CSII) therapy completed two 6-h conditions as follows: uninterrupted sitting (SIT) and sitting interrupted with 3-min bouts of simple resistance activities (SRAs) every 30 min. Basal and bolus insulin were standardized across conditions except in cases of hypoglycemia. Postprandial responses were assessed using incremental area-under-the-curve (iAUC) and total AUC (tAUC) from half-hourly venous sampling. Meal-based insulin sensitivity determined from glucose sensor and insulin pump (S i SP ) was assessed from flash continuous glucose monitor and insulin pump data. Outcomes were analyzed using mixed models adjusted for sex, BMI, treatment order, and preprandial values. Results: Glucose iAUC did not differ by condition (SIT: 19.8 ± 3.0 [estimated marginal means ± standard error] vs. SRA: 14.4 ± 3.0 mmol.6 h.L −1 ; P = 0.086). Despite CSII being standardized between conditions, insulin iAUC was higher in SRA compared to SIT (137.1 ± 22.7 vs. 170.9 ± 22.7 mU.6 h.L −1 ; P < 0.001). This resulted in a lower glucose response relative to the change in plasma insulin in SRA (tAUCglu/tAUCins: 0.32 ± 0.02 vs. 0.40 ± 0.02 mmol.mU −1 ; P = 0.03). Si SP was also higher at dinner following the SRA condition, with no between-condition differences at breakfast or lunch. Conclusion: Regularly interrupting prolonged sitting in T1D may increase plasma insulin and improve insulin sensitivity when meals and CSII are standardized. Future studies should explore underlying mechanistic determinants and the applicability of findings to those on multiple daily injections. Trial Registration: Australian and New Zealand Clinical Trial Registry Identifier-ACTRN12618000126213 ( www.anzctr.org.au ).


  • Open Access

    Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial

    by Jennifer A Halliday, Sienna Russell-Green, Benjamin Lam, Steven Trawley, Sybil A McAuley, Leon A Bach, Morton G Burt, Neale D Cohen, Peter G Colman, Elizabeth A Davis, et al.

    Introduction: This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy. Research design and methods: In this multicenter, open-label, randomized, controlled, parallel-group clinical trial, adults with T1D were allocated to 26 weeks of HCL (MiniMed™ 670G) or standard therapy (insulin pump or multiple daily injections without real-time continuous glucose monitoring). Psychological outcomes (awareness and fear of hypoglycemia; and diabetes-specific positive well-being, diabetes distress, diabetes treatment satisfaction, and diabetes-specific quality of life (QoL)) were measured at enrollment, mid-trial and end-trial. Linear mixed models were conducted, using restricted maximum likelihood estimation, unadjusted and adjusted (for covariates: age, sex, diabetes duration, glycated hemoglobin, recent severe hypoglycemia, pre-trial insulin delivery modality, enrollment and mid-study scores). Results: 120 participants (mean age 44±12 years) were randomized to intervention (n=61) or standard therapy (n=59). At 13 weeks, the HCL group had better diabetes-specific positive well-being than the standard therapy group (unadjusted: Δ=1.0, p=0.025; adjusted: Δ=1.1, p=0.01), which was maintained at 26 weeks (unadjusted: Δ=0.9, p=0.042; adjusted: Δ=1.0, p=0.023). At 26 weeks, the HCL group also had less diabetes distress (adjusted: Δ=−6.4, p=0.039), fear of hypoglycemia (“maintain high”: adjusted: Δ=−0.8, p=0.034; and “worry”: adjusted: Δ=−1.8, p=0.048), and perceived “unacceptably high glucose levels” (unadjusted: Δ=−1.1, p<0.001; adjusted: Δ=−1.1, p<0.001). HCL did not improve diabetes treatment satisfaction, diabetes-specific QoL, hypoglycemia awareness, or perceived frequency of unacceptably low glucose levels. Conclusions: These findings imply that HCL offers important psychological benefits. In particular, improvement in diabetes-specific positive well-being was observed 13 weeks after HCL initiation and maintained at 26 weeks. Reduction in the perceived frequency of hyperglycemia was also apparent by 26 weeks. Adjusted analyses showed significant reductions in diabetes distress and fear of hypoglycemia at 26 weeks, suggesting these benefits were apparent for people with particular characteristics. Trial registration number: Australian New Zealand Clinical Trials Registry: ACTRN12617000520336.